AstraZeneca and IMS Health announce real-world evidence collaboration in Europe

AstraZenecaAstraZeneca has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.

The partnership with IMS Health will give AstraZeneca access to pre-existing anonymised electronic health records, which include clinical outcome, economic and treatment pattern data. In addition, the companies will jointly develop a customised research and data analysis platform. The information will provide a deeper insight into how medicines that are already on the market are working in real-world settings across Europe, painting a picture of unmet needs in the current standard of care and treatment patterns across a number of therapeutic areas, with an emphasis on chronic illnesses. The data will also be used to inform AstraZeneca’s discovery and clinical development programmes.

Martin Mackay, AstraZeneca's President of Research and Development, said: "Our collaboration with IMS is a key milestone in our commitment to understand the impact of our medicines in the real world, beyond what we see in controlled clinical trials. This insight will help us and healthcare decision-makers to improve the treatment of disease and ensure effective use of medicines to minimise the burden on individuals and healthcare budgets."

Jon Resnick, IMS Health's Vice President of Real-World Evidence Solutions, said: "This joint initiative reflects a shared perspective on the transformative power of real-world evidence on global health systems. Our unique information assets, coupled with our services and technology capabilities, make IMS a leading partner for healthcare organisations in the identification, integration and interpretation of real-world outcomes. We are extremely pleased to be working with AstraZeneca on this collaboration."

The collaboration reflects the interest among healthcare decision-makers in examining the cost and effectiveness of new and existing medicines and health technologies to help allocate their increasingly limited resources more efficiently. Unlike controlled clinical trials, real-world evidence studies use observational data such as electronic medical records, claims information, patient registries and patient surveys. By evaluating the data associated with the delivery of care, 'real-world' analyses can demonstrate treatment impact on measurable outcomes such as hospital length of stay, readmissions, overall health status and total cost of care.

Today's announcement builds on AstraZeneca's existing 'real-world' data and research partnership with HealthCore in the US, the health outcomes research subsidiary of WellPoint.

The financial terms of the collaboration agreement are not disclosed.

About IMS Health
IMS Health is the leading provider of information, services and technology for the healthcare industry around the world. With a presence in more than 100 countries, the company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and consulting platforms to help clients better understand the performance and value of medicines.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Most Popular Now

Novartis confirms 5 year data for first and only f…

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension stud...

Researchers develop microneedle patch for flu vacc…

A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce rob...

Jardiance® (empagliflozin) analysis reinforces est…

An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (...

Alzheimer's and Parkinson's spurred by same enzyme

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors. But at ...

Researchers publish new findings on influence of h…

Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known. In a newly published study, Cleveland Cli...

Merck awards €1.25 million to research projects th…

Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the adva...

FDA tackles drug competition to improve patient ac…

Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower...

Trials show unique stem cells a potential asthma t…

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma. The Mo...

Roche acquires mySugr to form a leading open platf…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally...

Older Americans don't get - or seek - enough help …

The majority of Americans over age 50 take two or more prescription medicines to prevent or treat health problems, and many of them say the cost weighs on their budget, a...

Novartis CAR-T cell therapy CTL019 unanimously (10…

Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisag...

New brain cancer drug targets revealed

Researchers from Case Western Reserve University School of Medicine and The Cleveland Clinic designed a way to screen brain tumor cells and identify potential drug target...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]